Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
152.41
+0.40 (0.26%)
At close: Jun 27, 2025, 4:00 PM
152.42
+0.01 (0.01%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $21.89B in the quarter ending March 30, 2025, with 2.39% growth. This brings the company's revenue in the last twelve months to $89.33B, up 4.30% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$89.33B
Revenue Growth
+4.30%
P/S Ratio
4.06
Revenue / Employee
$646,857
Employees
138,100
Market Cap
366.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
| Thermo Fisher Scientific | 42.90B |
JNJ News
- 4 days ago - Johnson & Johnson: Undervalued Dividend King With 65% Upside Potential - Seeking Alpha
- 4 days ago - How To Build A $1,000,000 Dividend Portfolio That Could Yield 11%+ In 15 Years - Seeking Alpha
- 4 days ago - Best Dividend Kings: June 2025 - Seeking Alpha
- 5 days ago - IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC) - PRNewsWire
- 7 days ago - If I Could Only Buy 2 Dividend Stocks: June's Top Picks For Global Diversification - Seeking Alpha
- 9 days ago - Johnson & Johnson Hit With $8M Verdict in Massachusetts Mesothelioma Talc Lawsuit - Business Wire
- 11 days ago - Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan - CNBC
- 11 days ago - I'm Buying Dividend Aristocrats At Bargain Basement Prices - Seeking Alpha